Biophytis’ (BPTS) “Buy” Rating Reiterated at HC Wainwright

Biophytis (NASDAQ:BPTS)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued on Monday, The Fly reports.

Biophytis stock traded down $0.27 during midday trading on Monday, hitting $6.00. The company’s stock had a trading volume of 1,142 shares, compared to its average volume of 8,466. The stock’s 50-day moving average price is $8.38 and its 200-day moving average price is $10.27. Biophytis has a 12 month low of $6.00 and a 12 month high of $18.50.

About Biophytis

Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases and the treatment of severe respiratory failure in patients suffering from COVID-19. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases.

Read More: What are the advantages to having securities held in street name?

The Fly logo

Receive News & Ratings for Biophytis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biophytis and related companies with MarketBeat.com's FREE daily email newsletter.